Document is current
Any future updates will be listed below
-
Authors
Spiegel, Brennan M. R.
Eberlein, Samuel A.
Persky, Susan
Ishimori, Mariko L.
Venuturupalli, Swamy
Tu, Joseph
Alhatem, Fadi
Vijjeswarapu, Mary A.
Krut, Zoe
Norris, Tom
Choi, So Yung
Tighiouart, Mourad
Ross, Lindsey
Vrahas, Mark
Liran, Omer
Danovitch, Itai
Vuong, Tinh
Fouladian, Joshua
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (UH3AR076573)
National Center for Advancing Translational Sciences (UL1TR001881)
The Marc and Sheri Rapaport Fund for Digital Health Science and Precision Health at Cedars-Sinai
- License Information
-
More Information
Article History
Received: 27 August 2025
Accepted: 5 February 2026
First Online: 16 February 2026
Competing interests
: The authors have no conflicts of interest to declare. AppliedVR, the manufacturer of RelieVRx, participated in the Cedars-Sinai Accelerator in partnership with Techstars in 2016; however, none of the authors are employed by AppliedVR, hold equity in the company, receive royalties from the company, or benefit financially from the Cedars-Sinai Accelerator. One author (B.S.) serves on the Editorial Board of npj Digital Medicine but had no involvement in the review, handling, or decision-making related to this manuscript.
